MTEM
closedClinical-stage biopharmaceutical company focused on the discovery and development of the next generation of immunotoxins called engineered toxin bodies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $9.5m | Post IPO Equity | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 202 % | 168 % | (20 %) | 148 % | (49 %) | 166 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (919 %) | (389 %) | (236 %) | (638 %) | (207 %) | (445 %) | (5 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (961 %) | (416 %) | (356 %) | (671 %) | (215 %) | (469 %) | (15 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 394 % | 415 % | 259 % | 595 % | 219 % | 417 % | 93 % |
Source: Company filings or news article
Related Content
Molecular Templates is a biotechnology company dedicated to the discovery, development, and commercialization of next-generation immunotoxins known as Engineered Toxin Bodies (ETBs) for the treatment of cancer. The company operates in the biopharmaceutical sector, focusing on innovative cancer therapies that leverage the unique properties of ETBs to target and destroy cancer cells while minimizing damage to healthy tissues.
Molecular Templates primarily serves oncology patients and healthcare providers, aiming to address unmet medical needs in cancer treatment. The company's business model revolves around research and development (R&D) of ETBs, followed by clinical trials to ensure safety and efficacy. Revenue is generated through partnerships, licensing agreements, and eventual commercialization of approved therapies.
The market Molecular Templates operates in is highly competitive and regulated, with significant growth potential due to the increasing demand for effective cancer treatments. The company differentiates itself through its proprietary ETB technology, which offers a novel mechanism of action compared to traditional cancer therapies.
Key clients include pharmaceutical companies, research institutions, and healthcare providers who are involved in cancer treatment and research. By focusing on innovative solutions and strategic collaborations, Molecular Templates aims to bring breakthrough therapies to market, improving patient outcomes and advancing the field of oncology.
Keywords: immunotoxins, Engineered Toxin Bodies, cancer treatment, biotechnology, oncology, R&D, clinical trials, targeted therapy, biopharmaceutical, innovative cancer therapies.